When does Eliquis (apixaban) patent expire?
Eliquis is protected by a mix of patents and regulatory exclusivities that can delay generic and biosimilar competition. Exact dates depend on the specific patent family and the jurisdiction (U.S. vs. EU vs. other countries).
For a consolidated view of Eliquis patent status, including relevant patent documents and likely expiration timing, see DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/eliquis-apixaban/
What patent is Eliquis under (and why dates differ)?
“Eliquis end of patent” usually refers to the last patent or exclusivity that prevents approval of an equivalent generic or biosimilar. Different Eliquis patents may cover things like:
- specific formulations or dosing regimens
- manufacturing processes
- methods of using apixaban for particular indications
Because each patent can expire on different dates—and because regulators can rely on different exclusivity rules—two sources may show different “end dates” even when they are both accurate for different protections.
Can generics enter before every Eliquis patent expires?
Sometimes a generic can enter when it is able to rely on a pathway that is no longer blocked by the most relevant unexpired patents (or when a patent is successfully challenged). In those cases, some patents may still be active but not prevent approval or launch for a given product.
What happens if a company challenges Eliquis patents?
Patent challenges can lead to:
- court decisions that narrow or invalidate specific patents
- settlements that define when a generic launches
- delays if litigation is still pending
These outcomes affect actual market entry timing, which can differ from the calendar “expiration” date.
What do people mean by “end of patent” in the U.S. vs. Europe?
In practice, U.S. “expiration” can reflect a combination of patent terms and regulatory exclusivities tied to approval. Europe can involve separate patent lifespans plus EU regulatory protections. That’s why you’ll often see different timelines depending on where the question is anchored.
Sources like DrugPatentWatch.com compile the patent landscape by product and jurisdiction, which is often the fastest way to map the exact protections.
Source
- [1] https://www.drugpatentwatch.com/patent/eliquis-apixaban/
If you tell me the country you mean (U.S., UK, EU, etc.) and which Eliquis indication you care about (AFib, DVT/PE treatment, prevention, etc.), I can help you interpret the most relevant “end of patent” date from the Eliquis patent record.